Preclinical neurology work advanced two mechanistic directions toward restoring function and protecting neurons. A rat Parkinson’s model study reported that a selective, brain-penetrant CD38 inhibitor increased NAD+ levels in the brain, protected dopaminergic neurons from alpha-synuclein toxicity in vitro, and reduced motor deficits. Separately, mechanistic research addressed inflammatory signaling in gut disease models by targeting aryl hydrocarbon receptor (AHR) pathways, which reduced IL-8 expression in a lab model of intestinal inflammation. While not the same disease area, both threads reflect an industry-wide interest in modulating endogenous metabolic or inflammatory circuits rather than only downstream endpoints. For drug developers, the CD38/NAD+ angle remains particularly notable because it offers a relatively clear target engagement framework, including measurable biochemical changes in relevant tissues. The immediate limitation across such work is translational uncertainty: animal outcomes and cytokine modulation need careful confirmation for efficacy, safety, and dosing in humans.